SA
MSADY logo
MS&AD Insurance Group Holdings, Inc.(MSADY)
Closing price · checked 10:52 PM ETAbout this dataData status
$31.51▲0.23 (0.74%)
Extended:$31.51+0.00 (+0.00%)· 10:52 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

MS&AD Insurance Group Holdings, Inc. (MSADY)

Stock-Based Compensation

¥0.00

TTM · Period ending: · JPY

MSADY logo

MSADY Stock-Based Compensation

Latest reported¥0.00 JPY
MSADY Stock-Based Comp · JPY (¥0.00 → ¥0.00)
High-resolution chart · PNG

What is stock-based compensation?

Non-cash compensation expense paid in equity.

MSADY stock-based compensation history

Annual fiscal periods · JPY. Dates are reporting period ends; fiscal years can differ from calendar years. Change compares each value with the period before it.

MS&AD Insurance Group Holdings, Inc. Stock-Based Compensation — Annual fiscal periods (JPY)
Period endingStock-Based Compensation (JPY)Change
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—
0—

Frequently asked questions: MSADY stock-based compensation

What is MS&AD Insurance Group Holdings, Inc. (MSADY)'s current stock-based compensation?

MS&AD Insurance Group Holdings, Inc. (MSADY)'s latest reported stock-based compensation (TTM) is ¥0.00 as of Jun 30, 2026. Non-cash compensation expense paid in equity.

How much historical stock-based compensation data is available for MSADY?

Stock Alarm Pro provides 25 dated annual fiscal periods observations for MS&AD Insurance Group Holdings, Inc. (MSADY)'s stock-based compensation, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.

How can I compare MSADY's stock-based compensation to peers or set an alert?

You can open MSADY's stock-based compensation in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on MSADY delivered by push, email, or phone call.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.